Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $1.31 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Movano (MOVE) Misses Q2 EPS by 195c